EndoVascular Technologies restarts clinical trial of tube EndoGraft.
This article was originally published in The Gray Sheet
Executive SummaryENDOVASCULAR TECHNOLOGIES' TUBE ENDOGRAFT TRIALS RECOMMENCE following FDA approval of a design change to the implantable device's attachment system, the company says. Patient enrollment has begun for a Phase II study of EVT's Endovascular Grafting System incorporating the modified version of the tube EndoGraft.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.